United States of America
Factsheet| EV/EBITDA Last | EV/EBITDA(e) 2024 | EV/EBITDA NTM | |
|---|---|---|---|
| Adamis Pharmaceuticals Corp. | Free trial | Free trial | Free trial |
| International Peers | Free trial | Free trial | Free trial |
| Pharmaceuticals | 2.14 | 6.78 | 6.85 |
| N/A | N/A | N/A | N/A |
| United States of America | 3.69 | 9.06 | 8.54 |
Adamis Pharmaceuticals Corp. (Formerly Cellegy Pharmaceuticals, Inc.) |
| Sector: Pharmaceuticals | Ticker: ADMP |
|
"The Risk Score is a relevant measure for the assessment of a stock attractiveness. Adamis Pharmaceuticals Corp. shows a Risk Score of N/A.
0 corresponds to a very high risk and 10 corresponds to a very low risk."
The Risk Score for Adamis Pharmaceuticals Corp. is lower than its peer group's. This means that Adamis Pharmaceuticals Corp. is more risky than its peer group.
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
To analyze and assess the risk of a company, several indicators are important to look at including liquidity / volatility / debt level and capital structure. In GPRV, the aggregated Risk Score is the average of the risk indicators' scores.
Beta
The Beta is a quantitative measure of the volatility of a stock relatively to the volatility of the market. The Beta currently displayed is the 1 year Beta.
Volatility
Infront Analytics uses a method of estimating volatilities based on 3 months (62 business days) historical market value fluctuations.
Volume (3-Month daily average)
Volume indicator is the average of the daily volume over the last three months in $ millions.
Market Cap
Last close Market Capitalization in $ millions.
Net Debt/Market Cap
This is the Solvency measure, it guarantees that the company has a sound capital structure.
Calculation:
Last published net debt / Last market cap.
